Personalized medicine in breast cancer: pharmacogenomics approaches

References

• Wang C, Machiraju R, Huang K. Breast cancer patient stratification using a molecular regularized consensus clustering method. Methods. 2014;67(3):304–312. doi:10.1016/j.ymeth.2014.03.00524657666
   PubMed Web of Science ®Google Scholar
• Chen X, Shachter RD, Kurian AW, Rubin DL. Dynamic strategy for personalized medicine: an application to metastatic breast cancer. J Biomed Inform. 2017;68:50–57. doi:10.1016/j.jbi.2017.02.01228232241
   PubMed Web of Science ®Google Scholar
• Nerenz RD. Pharmacogenomics and personalized medicine in the treatment of human diseases. In: Coleman WB, Tsongalis GJ, editors. Molecular pathology. 2nd ed. Elsevier; New York: Chapel Hill; 2018;731–743.
   Google Scholar
• Li H, Jia W. Cometabolism of microbes and host: implications for drug metabolism and drug‐induced toxicity. Clin Pharmacol Ther. 2013;94(5):574–581. doi:10.1038/clpt.2013.15723933971
   PubMed Web of Science ®Google Scholar
• Nandy A, Gangopadhyay S, Mukhopadhyay A. Individualizing breast cancer treatment—the dawn of personalized medicine. Exp Cell Res. 2014;320(1):1–11. doi:10.1016/j.yexcr.2013.09.00224051330
   PubMed Web of Science ®Google Scholar
• Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83–94. doi:10.1016/j.jsps.2013.02.00324648818
   PubMed Web of Science ®Google Scholar
• Dickmann LJ, Ware JA. Pharmacogenomics in the age of personalized medicine. Drug Discov Today Technol. 2016;21:11–16. doi:10.1016/j.ddtec.2016.11.00327978982
   PubMedGoogle Scholar
• Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev. 2012;38(6):698–707. doi:10.1016/j.ctrv.2011.11.00522178455
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747. doi:10.1038/3502055710963602
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–10874. doi:10.1073/pnas.19136709811553815
   PubMed Web of Science ®Google Scholar
• Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8(5):R76. doi:10.1186/gb-2007-8-5-r8117493263
   PubMed Web of Science ®Google Scholar
• Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5(1):5–23. doi:10.1016/j.molonc.2010.11.00321147047
   PubMed Web of Science ®Google Scholar
• Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16(Supplement 1):61–70. doi:10.1634/theoncologist.2011-S1-61
   Web of Science ®Google Scholar
• Sørlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc National Acad Sci. 2003;100(14):8418–8423. doi:10.1073/pnas.0932692100
   PubMed Web of Science ®Google Scholar
• Stefansson OA, Esteller M. Epigenetic modifications in breast cancer and their role in personalized medicine. Am J Pathol. 2013;183(4):1052–1063. doi:10.1016/j.ajpath.2013.04.03323899662
   PubMed Web of Science ®Google Scholar
• Gnant M, Harbeck N, St. Gallen TC. summary of the consensus discussion. Breast Care. 2011;6(2):136–141.21633630
   PubMed Web of Science ®Google Scholar
• Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. Lancet. 2015;385(9980):1863–1872. doi:10.1016/S0140-6736(14)62048-125740286
   PubMed Web of Science ®Google Scholar
• Creighton CJ. The molecular profile of luminal B breast cancer. Biologics. 2012;6:289.22956860
   PubMedGoogle Scholar
• Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–5685. doi:10.1158/1078-0432.CCR-04-242116115903
   PubMed Web of Science ®Google Scholar
• Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61. doi:10.1038/nature1141223000897
   PubMed Web of Science ®Google Scholar
• Colozza M, de Azambuja E, Cardoso F, Bernard C, Piccart MJ. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era. Oncologist. 2006;11(2):111–125. doi:10.1634/theoncologist.11-2-11116476832
   PubMed Web of Science ®Google Scholar
• Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295(21):2492–2502. doi:10.1001/jama.295.21.249216757721
   PubMed Web of Science ®Google Scholar
• Rakha EA, El-Rehim DA, Paish C, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer. 2006;42(18):3149–3156. doi:10.1016/j.ejca.2006.08.01517055256
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-022015328174
   PubMed Web of Science ®Google Scholar
• Weigelt B, Mackay A, A‘Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;11(4):339–349. doi:10.1016/S1470-2045(10)70008-520181526
   PubMed Web of Science ®Google Scholar
• Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. doi:10.1186/bcr272220813035
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Traina TA, King TA. Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. Surg Oncol Clin. 2013;22(4):823–840. doi:10.1016/j.soc.2013.06.006
   PubMed Web of Science ®Google Scholar
• Fang L, Barekati Z, Zhang B, Liu Z, Zhong X. Targeted therapy in breast cancer: what’s new. Swiss Med Wkly. 2011;141:w13231.21706452
   PubMed Web of Science ®Google Scholar
• Ng CK, Martelotto LG, Gauthier A, et al. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol. 2015;16(1):107. doi:10.1186/s13059-015-0667-425994018
   PubMed Web of Science ®Google Scholar
• Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol. 2015;12(7):381. doi:10.1038/nrclinonc.2015.7325895611
   PubMed Web of Science ®Google Scholar
• Tsai H-F, Trubelja A, Shen AQ, Bao G. Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment. J R Soc Interface. 2017;14(131):20170137. doi:10.1098/rsif.2017.013728637915
   PubMed Web of Science ®Google Scholar
• Ahn J, Sei Y, Jeon N, Kim Y. Tumor microenvironment on a chip: the progress and future perspective. Bioengineering. 2017;4(3):64. doi:10.3390/bioengineering4020044
   Google Scholar
• Peters ML, Garber JE, Tung N. Managing hereditary breast cancer risk in women with and without ovarian cancer. Gynecol Oncol. 2017;146(1):205–214. doi:10.1016/j.ygyno.2017.04.01328454658
   PubMed Web of Science ®Google Scholar
• Kristiansen S, Nielsen D, Sölétormos G. Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer. Clin Epigen. 2016;8(1):35. doi:10.1186/s13148-016-0199-0
   Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.10592173
   PubMed Web of Science ®Google Scholar
• Sangodkar J, Farrington CC, McClinch K, Galsky MD, Kastrinsky DB, Narla G. All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase. FEBS J. 2016;283(6):1004–1024. doi:10.1111/febs.1357326507691
   PubMed Web of Science ®Google Scholar
• Lau QC, Raja E, Salto-Tellez M, et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res. 2006;66(13):6512–6520. doi:10.1158/0008-5472.CAN-06-036916818622
   PubMed Web of Science ®Google Scholar
• Pietras RJ, Márquez-Garbán DC. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin Cancer Res. 2007;13(16):4672–4676. doi:10.1158/1078-0432.CCR-07-137317699844
   PubMed Web of Science ®Google Scholar
• Russell CA. Personalized medicine for breast cancer: it is a new day! Am J Surg. 2014;207(3):321–325. doi:10.1016/j.amjsurg.2013.10.01624581758
   PubMed Web of Science ®Google Scholar
• Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010;15;16(10):1078–1432. CCR-09-1753.
   Web of Science ®Google Scholar
• De Abreu FB, Wells WA, Tsongalis GJ. The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. Am J Pathol. 2013;183(4):1075–1083. doi:10.1016/j.ajpath.2013.07.00223920325
   PubMed Web of Science ®Google Scholar
• Yanagawa T, Kagara N, Miyake T, et al. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing. Breast Cancer Res Treat. 2017;163(2):231–240. doi:10.1007/s10549-017-4190-z28283903
   PubMed Web of Science ®Google Scholar
• Mayer IA. Advanced hormone-sensitive breast cancer: overcoming resistance. J Natl Compr Canc Netw. 2015;13(5S):655–657.25995422
   PubMed Web of Science ®Google Scholar
• Downey C, Simpkins S, White J, et al. The prognostic significance of tumour–stroma ratio in oestrogen receptor-positive breast cancer. Br J Cancer. 2014;110(7):1744. doi:10.1038/bjc.2014.6924548861
   PubMed Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget. 2016;7(22):32504. doi:10.18632/oncotarget.883927102299
   PubMedGoogle Scholar
• Tabarestani S, Motallebi M, Akbari ME. Are estrogen receptor genomic aberrations predictive of hormone therapy response in breast cancer? Iran J Cancer Prev. 2016;9:4. doi:10.17795/ijcp
   Google Scholar
• Segal CV, Dowsett M. Estrogen receptor mutations in breast cancer—new focus on an old target. Clin Cancer Res. 2014;20(7):1724–1726. doi:10.1158/1078-0432.CCR-14-006724583794
   PubMed Web of Science ®Google Scholar
• Fribbens C, O‘Leary B, Kilburn L, et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2016;34:2961–2968.
   Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. doi:10.1016/S1470-2045(15)00613-026947331
   PubMed Web of Science ®Google Scholar
• Lauring J, Wolff AC. Evolving role of the estrogen receptor as a predictive biomarker: ESR1 mutational status and endocrine resistance in breast cancer. J Clin Oncol. 2016;34(25):2950–2952. doi:10.1200/JCO.2016.68.472027382095
   PubMed Web of Science ®Google Scholar
• Gelsomino L, Gu G, Rechoum Y, et al. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling. Breast Cancer Res Treat. 2016;157(2):253–265. doi:10.1007/s10549-016-3829-527178332
   PubMed Web of Science ®Google Scholar
• Fuqua SA, Gu G, Rechoum Y. Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat. 2014;144(1):11–19. doi:10.1007/s10549-014-2847-424487689
   PubMed Web of Science ®Google Scholar
• Fu X, Creighton CJ, Biswal NC, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014;16(5):430. doi:10.1186/s13058-014-0492-925212826
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Wiechmann LS, Wang Y-C, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res. 2011;17(6):1351–1361. doi:10.1158/1078-0432.CCR-10-190521138857
   PubMed Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Analysis of ESR1 and PIK3CA mutations in plasma cell-free DNA from ER-positive breast cancer patients. Oncotarget. 2017;8(32):52142. doi:10.18632/oncotarget.1847928881720
   PubMedGoogle Scholar
• Van Loo P, Wedge D, Nik-Zainal S, Stratton M, Futreal P, Campbell P. 5 proffered paper: the life history of 21 breast cancers. Eur J Cancer. 2012;48:S2. doi:10.1016/S0959-8049(12)70709-8
   Web of Science ®Google Scholar
• Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, et al. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens. Transl Res. 2015;166(6):540–53. e2. doi:10.1016/j.trsl.2015.09.00326434753
   PubMed Web of Science ®Google Scholar
• Perez EA. Treatment strategies for advanced hormone receptor-positive and human epidermal growth factor 2-negative breast cancer: the role of treatment order. Drug Resist Update. 2016;24:13–22. doi:10.1016/j.drup.2015.11.001
   PubMed Web of Science ®Google Scholar
• Zanardi E, Bregni G, De Braud F, Di Cosimo S, editors. Better together: targeted combination therapies in breast cancer. Semin Oncol. 2015. Elsevier. doi:10.1053/j.seminoncol.2015.09.029
   Web of Science ®Google Scholar
• Garber JE, Halabi S, Tolaney SM, et al. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. J Natl Cancer Inst. 2010;102(13):942–949. doi:10.1093/jnci/djq21120554945
   PubMedGoogle Scholar
• Onitilo AA, McCarty CA, Wilke RA, et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat. 2009;115(3):643–650. doi:10.1007/s10549-008-0264-219082882
   PubMed Web of Science ®Google Scholar
• Conway K, Parrish E, Edmiston SN, et al. The estrogen receptor-α A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res. 2005;7(6):R871. doi:10.1186/bcr94916280033
   PubMed Web of Science ®Google Scholar
• Roodi N, Bailey LR, Kao W-Y, et al. Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. Jnci. 1995;87(6):446–451. doi:10.1093/jnci/87.6.4467861463
   PubMedGoogle Scholar
• Weinreb I, Piscuoglio S, Martelotto LG, et al. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet. 2014;46(11):1166. doi:10.1038/ng.289525240283
   PubMed Web of Science ®Google Scholar
• Ross JS, Gay LM, Wang K, et al. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: an emerging opportunity for anti‐HER2 targeted therapies. Cancer. 2016;122(17):2654–2662. doi:10.1002/cncr.3010227284958
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc National Acad Sci. 1992;89(10):4285–4289. doi:10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011;11(2):263–275. doi:10.1586/era.10.22621342044
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–792. doi:10.1056/NEJM20010315344110111248153
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–726. doi:10.1200/JCO.2002.20.3.71911821453
   PubMed Web of Science ®Google Scholar
• Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer. 2008;8(4):324–333. doi:10.3816/CBC.2008.n.03718757259
   PubMed Web of Science ®Google Scholar
• Nahta R, Esteva F. Trastuzumab: triumphs and tribulations. Oncogene. 2007;26(25):3637. doi:10.1038/sj.onc.121037917530017
   PubMed Web of Science ®Google Scholar
• Bedard PL, de Azambuja E, Cardoso F. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer. Curr Cancer Drug Targets. 2009;9(2):148–162.19275756
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111–128.
   Web of Science ®Google Scholar
• Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9(1):16. doi:10.1038/nrclinonc.2012.154
   Web of Science ®Google Scholar
• Yamaguchi H, Chang S, Hsu J, Hung M. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 2014;33(9):1073. doi:10.1038/onc.2013.7423542173
   PubMed Web of Science ®Google Scholar
• Arribas J, Baselga J, Pedersen K, Parra-Palau JL. p95HER2 and breast cancer. Cancer Res. 2011;71(5):1515–1519. doi:10.1158/0008-5472.CAN-10-379521343397
   PubMed Web of Science ®Google Scholar
• Castiglioni F, Tagliabue E, Campiglio M, Pupa S, Balsari A, Menard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer. 2006;13(1):221–232. doi:10.1677/erc.1.0104716601290
   PubMed Web of Science ®Google Scholar
• Mitra D, Brumlik MJ, Okamgba SU, et al. An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance. Mol Cancer Ther. 2009;8(8):2152–2162. MCT-09-0295.
   Web of Science ®Google Scholar
• Funes M, Miller JK, Lai C, Carraway KL, Sweeney C. The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem. 2006;281(28):19310–19319. doi:10.1074/jbc.M60322520016690615
   PubMed Web of Science ®Google Scholar
• Price‐Schiavi SA, Jepson S, Li P, et al. Rat Muc4 (sialomucin complex) reduces binding of anti‐ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer. 2002;99(6):783–791. doi:10.1002/ijc.1041012115478
   PubMed Web of Science ®Google Scholar
• de Melo Gagliato D, Jardim DLF, Marchesi MSP, Hortobagyi GN. Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget. 2016;7(39):64431.26824988
   PubMed Web of Science ®Google Scholar
• Ferrari A, Vincent-Salomon A, Pivot X, et al. A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun. 2016;7:12222. doi:10.1038/ncomms1222227406316
   PubMed Web of Science ®Google Scholar
• Kovtun YV, Goldmacher VS. Cell killing by antibody–drug conjugates. Cancer Lett. 2007;255(2):232–240. doi:10.1016/j.canlet.2007.04.01017553616
   PubMed Web of Science ®Google Scholar
• Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16(2):209. doi:10.1186/s13058-014-0492-924887180
   PubMed Web of Science ®Google Scholar
• Van Herpen C, Banerji U, Mommers E, et al. 333 Phase I dose-escalation trial with the DNA-alkylating anti-HER2 antibody-drug conjugate SYD985. Eur J Cancer. 2015;51:S65. doi:10.1016/S0959-8049(16)30197-6
   Web of Science ®Google Scholar
• Medina PJ, Goodin S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther. 2008;30(8):1426–1447. doi:10.1016/j.clinthera.2008.08.00818803986
   PubMed Web of Science ®Google Scholar
• Tevaarwerk AJ, Kolesar JM. Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009;31:2332–2348. doi:10.1016/j.clinthera.2009.11.02920110044
   PubMed Web of Science ®Google Scholar
• Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006;66(3):1630–1639. doi:10.1158/0008-5472.CAN-05-118216452222
   PubMed Web of Science ®Google Scholar
• Vicario R, Peg V, Morancho B, et al. Patterns of HER2 gene amplification and response to anti-HER2 therapies. PLoS One. 2015;10(6):e0129876. doi:10.1371/journal.pone.012987626075403
   PubMed Web of Science ®Google Scholar
• Hafizi S, Dahlbäck B. Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases. Cytokine Growth Factor Rev. 2006;17(4):295–304. doi:10.1016/j.cytogfr.2006.04.00416737840
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, De Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–328.15093539
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J clin oncol. 2005;23(11):2534–2543. doi:10.1200/JCO.2005.03.18415699478
   PubMed Web of Science ®Google Scholar
• Leung W-Y, Roxanis I, Sheldon H, et al. Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget. 2015;6(8):5678. doi:10.18632/oncotarget.329625691057
   PubMedGoogle Scholar
• Hyman D, Piha-Paul S, Rodón J, et al. editors. Neratinib for ERBB2 mutant, HER2 non-amplified, metastatic breast cancer: preliminary analysis from a multicenter, open-label, multi-histology phase II basket trial. Cancer Res. 2016. AMER ASSOC CANCER RESEARCH 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA …. doi:10.1158/1538-7445.SABCS15-PD5-05
   Web of Science ®Google Scholar
• Subramaniam D, He A R, Hwang J, et al. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer. Curr Cancer Drug Targets. 2014;14(9):775–793. doi:10.2174/1568009614666141111104643
   Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17(3):367–377. doi:10.1016/S1470-2045(15)00551-326874901
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008;27(34):4702. doi:10.1038/onc.2008.10918408761
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Shatsky R, Harbeck N. Afatinib in the treatment of breast cancer. Expert Opin Investig Drugs. 2014;23(7):1039–1047. doi:10.1517/13543784.2014.924505
   PubMed Web of Science ®Google Scholar
• Gunzer K, Joly F, Ferrero J-M, et al. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. Springerplus. 2016;5(1):45. doi:10.1186/s40064-015-1601-726835225
   PubMedGoogle Scholar
• Judes G, Rifaï K, Daures M, et al. High-throughput «Omics» technologies: new tools for the study of triple-negative breast cancer. Cancer Lett. 2016;382(1):77–85. doi:10.1016/j.canlet.2016.03.00126965997
   PubMed Web of Science ®Google Scholar
• Telli ML, Hellyer J, Audeh W, et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat. 2018;168(3):625–630. doi:10.1007/s10549-017-4624-729275435
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395. doi:10.1038/nature1093322495314
   PubMed Web of Science ®Google Scholar
• Foedermayr M, Sebesta M, Rudas M, et al. BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy. Cancer Chemother Pharmacol. 2014;73(4):771–778. doi:10.1007/s00280-014-2404-124526178
   PubMed Web of Science ®Google Scholar
• Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38. doi:10.1186/bcr152216846527
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864. doi:10.1038/sj.onc.120987416998501
   PubMed Web of Science ®Google Scholar
• O‘Shaughnessy J, Schwartzberg L, Danso M, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29(15_suppl):1007. doi:10.1200/jco.2011.29.15_suppl.100721205758
   PubMed Web of Science ®Google Scholar
• Patel AG, De Lorenzo SB, Flatten KS, Poirier GG, Kaufmann SH. Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro. Clin Cancer Res. 2012;15;18(6):1655–1662.
   Web of Science ®Google Scholar
• Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7(10):2984–2997.11595686
   PubMed Web of Science ®Google Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Breast Cancer Chemosensitivity. 2007;608:1–22.
   Google Scholar
• Gewirtz D. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727–741. doi:10.1016/S0006-2952(98)00307-410075079
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229. doi:10.1124/pr.56.2.615169927
   PubMed Web of Science ®Google Scholar
• Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism—a strategy for overcoming drug resistance. J Natl Cancer Inst. 2001;93(5):347–357.11238696
   PubMedGoogle Scholar
• Chen G, J-P J, Fleming WH, Durán GE, Sikic BI. Prevalence of multidrug resistance related to activation of the mdr1 gene in human sarcoma mutants derived by single-step doxorubicin selection. Cancer Res. 1994;54(18):4980–4987.7915196
   PubMed Web of Science ®Google Scholar
• Larsen AK, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta. 1998;1400(1–3):257–274. doi:10.1016/S0167-4781(98)00140-79748618
   PubMed Web of Science ®Google Scholar
• Withoff S, De SJ, De EV, Mulder N. Human DNA topoisomerase II: biochemistry and role in chemotherapy resistance. Anticancer Res. 1996;16(4A):1867–1880.8712715
   PubMed Web of Science ®Google Scholar
• Finlay GJ, Baguley BC, Snow K, Judd W. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues. Jnci. 1990;82(8):662–667. doi:10.1093/jnci/82.8.6622157028
   PubMedGoogle Scholar
• Seidman AD, Reichman BS, Crown J, et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 1995;13(5):1152–1159. doi:10.1200/JCO.1995.13.5.11527537798
   PubMed Web of Science ®Google Scholar
• Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96 hr infusion. J Clin Oncol. 1994;12(8):1621–1629. doi:10.1200/JCO.1994.12.8.16217913721
   PubMed Web of Science ®Google Scholar
• Anderson H, Hopwood P, Prendiville J, Radford JA, Thatcher N, Ashcroft L. A randomised study of bolus vs continuous pump infusion of ifosfamide and doxorubicin with oral etoposide for small cell lung cancer. Br J Cancer. 1993;67(6):1385. doi:10.1038/bjc.1993.2568390287
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Taxol® (paclitaxel) [Prescribing information]. New York: Bristol-Myers Squibb; 2011.
   Google Scholar
• Greenberger L, Williams SS, Horwitz SB. Biosynthesis of heterogeneous forms of multidrug resistance-associated glycoproteins. J Biol Chem. 1987;262(28):13685–13689.2888763
   PubMed Web of Science ®Google Scholar
• Tolcher A, Cowan K, Solomon D, et al. Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer. J clin oncol. 1996;14(4):1173–1184. doi:10.1200/JCO.1996.14.4.11738648372
   PubMed Web of Science ®Google Scholar
• Twelves C, Jove M, Gombos A, Awada A. Cytotoxic chemotherapy: still the mainstay of clinical practice for all subtypes metastatic breast cancer. Crit Rev Oncol Hematol. 2016;100:74–87. doi:10.1016/j.critrevonc.2016.01.02126857987
   PubMed Web of Science ®Google Scholar
• Jameson GS, Hamm JT, Weiss GJ, et al. A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res. 2013;19(1):268–278. doi:10.1158/1078-0432.CCR-12-120123136196
   PubMed Web of Science ®Google Scholar
• Hoch U, Staschen C-M, Johnson RK, Eldon MA. Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models. Cancer Chemother Pharmacol. 2014;74(6):1125–1137. doi:10.1007/s00280-014-2577-725228368
   PubMed Web of Science ®Google Scholar
• Huennekens F. The methotrexate story: a paradigm for development of cancer chemotherapeutic agents. Adv Enzyme Regul. 1994;34:397–419.7942284
   PubMedGoogle Scholar
• Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330. doi:10.1038/nrc107412724731
   PubMed Web of Science ®Google Scholar
• Grant SC, Kris MG, Young CW, Sirotnak FM. Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest. 1993;11(1):36–45.8422595
   PubMed Web of Science ®Google Scholar
• Sirotnak F, Moccio D, Kelleher L, Goutas L. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Research. 1981;41(11 Pt 1):4447–4452.
   Google Scholar
• Kool M, Van Der Linden M, de Haas M, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc National Acad Sci. 1999;96(12):6914–6919. doi:10.1073/pnas.96.12.6914
   PubMed Web of Science ®Google Scholar
• Hooijberg J, Broxterman H, Scheffer G, et al. Potent interaction of flavopiridol with MRP1. Br J Cancer. 1999;81(2):269. doi:10.1038/sj.bjc.669068710496352
   PubMed Web of Science ®Google Scholar
• Cowan KH, Jolivet J. A methotrexate-resistant human breast cancer cell line with multiple defects, including diminished formation of methotrexate polyglutamates. J Biol Chem. 1984;259(17):10793–10800.6206061
   PubMed Web of Science ®Google Scholar
• Volk EL, Rohde K, Rhee M, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res. 2000;60(13):3514–3521.10910063
   PubMed Web of Science ®Google Scholar
• Ohmori T, Podack E, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun. 1993;192(1):30–36.8476431
   PubMed Web of Science ®Google Scholar
• Priest DG, Ledford BE, Doig MT. Increased thymidylate synthetase in 5-fluorodeoxyuridine resistant cultured hepatoma cells. Biochem Pharmacol. 1980;29(11):1549–1553.6446915
   PubMed Web of Science ®Google Scholar
• Spears CP. Clinical resistance to antimetabolites. Hematol Oncol Clin North Am. 1995;9(2):397–414.7642470
   PubMed Web of Science ®Google Scholar
• Klatt O, Stehlin JS, McBride C, Griffin A. The effect of nitrogen mustard treatment on the deoxyribonucleic acid of sensitive and resistant Ehrlich tumor cells. Cancer Res. 1969;29(2):286–290.5765411
   PubMed Web of Science ®Google Scholar
• Ichiro N, Kimitoshi K, Junko K, et al. Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem Pharmacol. 1989;38(3):519–527.2563655
   PubMed Web of Science ®Google Scholar
• Zamble DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci. 1995;20(10):435–439.8533159
   PubMed Web of Science ®Google Scholar
• Perez R. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 1998;34(10):1535–1542.9893624
   PubMed Web of Science ®Google Scholar
• Moudi M, Go R, Yien CYS, Nazre M. Vinca alkaloids. Int J Prev Med. 2013;4(11):1231.24404355
   PubMedGoogle Scholar
• Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36–48. doi:10.1016/j.addr.2012.09.03723036225
   PubMed Web of Science ®Google Scholar
• Coyle C, Cafferty F, Vale C, Langley R. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(12):2184–2195. doi:10.1093/annonc/mdw41027681864
   PubMed Web of Science ®Google Scholar
• Zhang J, Li G, Chen Y, et al. Metformin Inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. J Cancer. 2017;8(10):1849. doi:10.7150/jca.1985828819383
   PubMed Web of Science ®Google Scholar
• Al-Zaidan L, Ruz E, Abu R, Malki AM. Screening novel molecular targets of metformin in breast cancer by proteomic approach. Front Public Health. 2017;5:277. doi:10.3389/fpubh.2017.0008129085821
   PubMed Web of Science ®Google Scholar
• Obaidi J, Musallam E, Al-Ghzawi HM, Azzeghaiby SN, Alzoghaibi IN. Vitamin D and its relationship with breast cancer: an evidence based practice paper. Glob J Health Sci. 2015;7(1):261.
   Google Scholar
• Gall TL, Kristjansson E, Charbonneau C, Florack P. A longitudinal study on the role of spirituality in response to the diagnosis and treatment of breast cancer. J Behav Med. 2009;32(2):174–186. doi:10.1007/s10865-008-9182-318982441
   PubMed Web of Science ®Google Scholar
• Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Rev Clin Onco. 2008;5(8):466. doi:10.1038/ncponc1134
   Web of Science ®Google Scholar
• MacArthur AC, Le ND, Abanto ZU, Gallagher RP. Occupational female breast and reproductive cancer mortality in British Columbia, Canada, 1950–94. Occup Med (Chic Ill). 2007;57(4):246–253. doi:10.1093/occmed/kqm002
   Web of Science ®Google Scholar
• Akbari ME, Kashani FL, Ahangari G, et al. The effects of spiritual intervention and changes in dopamine receptor gene expression in breast cancer patients. Breast Cancer. 2016;23(6):893–900. doi:10.1007/s12282-015-0658-z26597879
   PubMed Web of Science ®Google Scholar
• Hejazi SH, Ahangari G, Pornour M, et al. Evaluation of gene expression changes of serotonin receptors, 5-HT3AR and 5-HT2AR as main stress factors in breast cancer patients. Asian Pac J Cancer Prev. 2013;15(11):4455–4458. doi:10.7314/APJCP.2014.15.11.4455
   Google Scholar
• Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G. The microbiota of breast tissue and its association with tumours. Appl Environ Microbiol. 2016;AEM: 01235–16.
   Google Scholar
• Toga AW, Foster I, Kesselman C, et al. Big biomedical data as the key resource for discovery science. JAMIA. 2015;22(6):1126–1131. doi:10.1093/jamia/ocv07726198305
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: Breast cancer - Reference pathway; 2018 Available at: https://www.genome.jp/kegg-bin/show_pathway?map05224. Accessed May 15, 2019
   Google Scholar